Kiniksa Pharmaceuticals International, plc (KNSA)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Sanjiv K. Patel
|
CEO & Chairman of the Board | 2.24M | 11.6M | 1969 |
|
Dr. John F. Paolini FACC, M.D., Ph.D.
|
Executive VP & Chief Medical Officer | 1.13M | 3.37M | 1965 |
|
Mr. Eben Tessari
|
Consultant | 1.13M | 9.38M | 1982 |
|
Mr. Michael R. Megna CPA
|
Senior VP & Chief Accounting Officer | -- | -- | 1971 |
|
Ms. Mei Jang
|
Senior VP & Chief Technical Officer | -- | -- | -- |
|
Mr. Jonathan Kirshenbaum
|
Investor Relations Officer | -- | -- | -- |
|
Mr. Douglas J. Barry
|
Senior VP, Chief Legal Officer & Secretary | -- | -- | -- |
|
Ms. Martina Struck Ph.D.
|
Senior VP & Chief Regulatory Officer | -- | -- | -- |
|
Mr. Joseph Pirrello
|
Chief Business Officer | -- | -- | -- |
|
Mr. Aaron Young
|
Chief Intellectual Property Officer | -- | -- | -- |
Kiniksa Pharmaceuticals International, plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 366
Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Corporate Governance
Upcoming Events
October 27, 2026 at 12:30 PM UTC
Kiniksa Pharmaceuticals International, plc Earnings Date
